Overview

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Status:
Active, not recruiting

Trial end date:
2022-04-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Treatments:

Bumetanide
Diuretics